A phase 2/3, randomized, double-blind, placebo-controlled study of LMN-201 for treatment and prevention of C. Difficile infection
Active Project Grant Awarded Last action
- Award ID
- HT94252310959
- Recipient
-
Lumen Bioscience, Inc. UEI E9UJDT3BFUQ5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $16,288,194
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 78% complete
- Place of performance
- Seattle, WA 98103, USA
Award details come from USAspending.gov.
About this award
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded Lumen Bioscience, Inc. a $16,288,194 project grant to conduct a Phase 2/3 clinical trial evaluating LMN-201, an anti-infective therapeutic for the treatment and prevention of Clostridioides difficile (C. difficile) infection. The randomized, double-blind, placebo-controlled study will take place in Seattle, WA and is expected to be completed by September 14, 2027. Lumen Bioscience, a biotechnology company that specializes in biological research and development, has also been awarded federal contracts and subgrants to support the development of other biologic products, including an intranasal antibody cocktail delivery platform and oral vaccine candidates for diarrheal diseases.
Quick answers
Who received award HT94252310959?
HT94252310959 was awarded to Lumen Bioscience, Inc. by Defense Health Agency (Department of Defense) on September 15, 2023.
How much is award HT94252310959 worth?
$16,288,194 has been obligated on HT94252310959.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award